BioSpace News Archive

Ra Medical Systems, Inc. (NYSE American: RMED), a medical device company focusing on commercializing excimer laser systems to treat vascular and dermatological diseases, reports financial results for the three months ended March 31, 2021 and provides a business update.

Verastem, Inc. (Nasdaq: VSTM) (also known as Verastem Oncology), a biopharmaceutical company committed to advancing new medicines for patients battling cancer, today reported financial results for the three months ended March 31, 2021, highlighted recent progress and outlined key corporate objectives.

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, announced that it has commenced an underwritten public offering of 4,000,000 shares of its common stock.

STERIS plc announced changes to its Board of Directors. David Lewis, Board member since 2010 has announced that he will not stand for election when his term expires on July 29, 2021.

Recro Pharma, Inc. (“Recro”; NASD:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering.

Citius Pharmaceuticals, Inc. (“Citius” or the “Company”) (Nasdaq: CTXR) today announced that it will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium.

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today announced that findings from its Phase 1 trial evaluating the safety and pharmacologic profile of apitemograb in healthy volunteers were published in the peer-reviewed journal Advances in Therapy.

In the decade since the advent of CRISPR-Cas9 gene editing, researchers have used the technology to delete or change genes in a growing number of cell types.

SQZ Biotechnologies Company, a cell therapy company developing novel treatments for multiple therapeutic areas, reported financial results for the period ended March 31, 2021 and reviewed recent business highlights.

Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference